Welcome to our Spotlight on allogeneic CAR-T

Quick access to all the content in the latest RegMedNet Spotlight, including expert editorials, peer-reviewed journal content and more.

Like 0 Comment

Visit the Spotlight>>

Off-the-shelf cell products have been a dream for the cell therapy field since its incarnation and that dream may be realized as we move towards allogeneic CAR-T cells.

Over the past year, chimeric antigen receptors (CARs) have erupted onto the cell therapy market. These CARs are utilized in a variety of cell types and for a range of conditions; however, the most successful deployment of the technology has been in the autologous treatment of blood cancers with T-cells.

So far, autologous therapies have somewhat dominated the clinics and journals, but, as our understanding of the therapy advances, eyes are turning towards the ability to mass-produce allogeneic CAR-T products for a lower cost and an ability to reach more patients.

However, there remain several significant difficulties. What kind of materials do you require? What are the logistical challenges? How do you ensure quality? In this Spotlight we will be examining CAR-T and its journey to an allogeneic cell therapy. With expert opinions from industry leaders, we will be looking at the necessities in manufacturing, the solutions available and some of the issues the field has to address.

Finally, we will hear from leading experts in the field who will review ethical and regulatory developments that could impact developers and patients.

Visit the Spotlight - new posts weekly!

Editor's picks

Here are our highlights from the feature. Find even more on the Spotlight page and look out for new content coming every week.

  • Take our survey on allogeneic CAR-T and help us investigate how you are utilizing the therapy in your work. SURVEY CLOSED
  • Hear from Senthil Ramaswamy, Head of Lonza's Cell and Gene Technologies, as he discusses his view on the transition to scaled up therapies. View now>>
  • See the new infographic from CellGenix about quality controlling T-cell manufacturing. Find out more>>
  • Catch Lonza's article on the challenges of scaling up therapies and moving from autologous CAR-T to allogeneic. Find out more>>
  • Read the Immunotherapy article on the novel CAR-T designed to target solid tumors, free for RegMedNet members. Find out more>>
  • Check out the specialized culture medium for T-cell production from CellGenix with this new article. View now>>
  • What is the future of allogeneic therapies? Marcos Langtry (Lonza Pharma & Biotech) explains in this exclusive interview. Read now>>
  • De-risk and industrialize cell and gene therapy: discover a process development roadmap. Find out more>>
  • Learn more about a highly efficient T-cell manufacturing process with reduced handling steps in this application note. View now>>
  • [PANEL DISCUSSION] Register now for our free event investigating current obstacles in allogeneic CAR-T development and possible future evolution. Register now>>

Visit the Spotlight for even more!

Go to the profile of RegMedNet


eCommunity, Future Science Group

RegMedNet is a networking site where users can share their knowledge and insights. This profile will share some content and updates from the RegMedNet team, including webinars, news and journal articles.

No comments yet.